Chengdu Weikang Biotech Secures Tens of Millions in Series A+ Funding to Accelerate Leadership in Clinical POCT Market

Recently, VACURE (Chengdu Weikang Biology), a rising star in China’s microfluidic POCT sector, announced the completion of itsTens of millions in Series A+ equity financing, this round of financing was led byHenan High-Tech Venture CapitalLead Investor,Hongzheng Lide Capital, Original ShareholdersShenzhen Xidao YunyingCo-investment. It is understood that this is Chengdu Weikang Biology'sSecond round of equity financing completed within the past six monthsPreviously, Chengdu Weikang Biotech had addressed the industry pain points of high costs and difficulties in stable mass production of microfluidic POCT products through multiple underlying technological innovations, and successfully developed a range of microfluidic POCT products based on its proprietary methodology: “Microfluidic Time-Resolved Immunofluorescence Assay.” Among these, the “China’s First Disc-Type Microfluidic Immunoassay Combo Testing POCT Diagnostic Platform” gained immediate favor from clinical departments of numerous Grade A tertiary hospitals upon its launch. The funds raised in this round of financing will be primarily used for product registration and approval submissions, development of new product lines, and expansion of sales channels, thereby accelerating the capture of the clinical POCT market and striving to establish a leading position in this niche segment.

Since its establishment in 2017, Chengdu Weikang Biology has leveraged multiple globally exclusive, leading proprietary technologies to pioneer a novel technological pathway for microfluidic point-of-care testing (POCT). It was the first to develop China’s inaugural “comprehensive microfluidic POCT solution,” strategically deploying vertically across four key sectors—immunodiagnostics, molecular diagnostics, coagulation testing, and home-use diagnostics—while rapidly expanding the range of detectable assays across its platforms horizontally. This approach has progressively met diagnostic needs across all levels and scenarios, spanning “home care, primary care, clinical settings, secondary hospitals, and tertiary hospitals.” Dr. Tang Yong, Founder and CEO, has dedicated over a decade to the in vitro diagnostics (IVD) industry, accumulating profound expertise in immunodiagnostics, molecular diagnostics, and raw material development. His leadership has attracted and assembled a highly capable and experienced core team.

Currently, Weikang has successfully developed three major product platforms: “Microfluidic Time-Resolved Immunofluorescence,” “Disc-Based Microfluidic Multiplex Immunoassay,” and “Modular Molecular Diagnostic Integrated Microfluidics,” and has obtainedMore than 30 Domestic Medical Device Registration Certificates，Over 60 EU CE Certifications, in additionDozens of Products in Development. It is worth noting that Weikang's microfluidic productsRaw Materials, Chips, Reagents, InstrumentsAll areSelf-developed and Self-manufactured, the product line demonstrates strong scalability, with diagnostic tests comprehensively covering major categories including cardiopulmonary, infectious diseases, blood-borne infections, respiratory infections, gastrointestinal, hormones, obstetrics and pediatrics, metabolic nutrition, and neurology. A range of diagnostic instruments with varying sizes, testing throughputs, and levels of automation has been developed and adapted to meet the needs of healthcare facilities from primary care settings to tertiary hospitals.

For a long time, the POCT market in clinical departments of tertiary hospitals has been monopolized by traditional imported products with outdated design concepts. These products are not only expensive but also complex to operate; their liquid reagents require cold-chain transportation and storage, need 15 minutes for rewarming before use, cannot achieve precise multi-analyte combined testing, and pose significant challenges in handling whole blood and samples with abnormal interferences, making them increasingly unable to meet the current clinical market’s practical demands for POCT.

Chengdu Weikang Biotech’s pioneering “DISKFLU Disc-Based Microfluidic Immunoassay Diagnostic Platform,” a leading product that fills a domestic gap, surpasses European and American counterparts with its novel underlying technology and design philosophy, perfectly meeting the stringent POCT requirements of clinical departments. By loading the sample only once onto the disc-based microfluidic chip, it canWithin 15 MinutesAuto-completion up to9 Projectsprecise quantitative detection.

withFive-Item Cardiopulmonary PanelTake joint inspection as an example:

1、Single Sample Addition, results for five chest pain biomarkers obtained simultaneously within 15 minutes;

2、High-Sensitivity TroponinDetection, achieved for the first time in a combined test;

3、Whole Blood Sample Addition, centrifuge to separate serum, free from blood cell interference, for more accurate detection;

4. Disc-based Microfluidics Technology for Multiplexed TestingNon-Interference, the analytical performance metrics are consistent with those of individual tests;

5. Patented ultra-low-temperature inkjet freeze-drying technology, reagent chips canStore at room temperature for 1 year, no cold chain required.

Flagship Disc-Based Microfluidic Multiplex Assay ProductCardiology Department, Emergency Department, Chest Pain Center, ICUIn the clinical POCT market for hospital departments, its systems are currently installed and in use at numerous Grade A tertiary hospitals across China. Moving forward, Weikang will further increase its investment in disc-based multiplex testing products. In addition to the already certified five-item and eight-item cardiopulmonary panels, the company will rapidly launch multiple multiplex testing products in areas such as preoperative assessment, gastrointestinal disorders, Helicobacter pylori genotyping, and respiratory diseases, thereby expanding its market share in the emerging clinical POCT sector, which is valued at tens of billions of yuan.

Dr. Tang Yong, Founder and CEO of Chengdu Weikang Biology, stated:Weikang Bio’s microfluidic POCT technology and products are at the forefront in China. Multiple product lines have been successfully commercialized, achieved mass production, and are sold across all provinces and municipalities in China. We extend our sincere gratitude to the investors in this round—Henan High-Tech Venture Capital, Hongzheng Lide Capital, and Shenzhen Xidao Yunying Financial Consulting Partnership (Limited Partnership)—for their recognition of Weikang Bio. We also thank our existing shareholders, including our Series A and angel-round investors, for their continued support. Weikang Bio will remain committed to innovation, continuously launching new products to rapidly expand its disc-based microfluidic multiplex testing portfolio, while accelerating the development of new platforms in molecular diagnostics, coagulation testing, and home-use settings. Our goal is to provide precise, rapid, and convenient in vitro diagnostic products for clinical departments and primary healthcare institutions, striving to realize our vision of becoming a comprehensive “microfluidic POCT full-scenario solution” provider and emerging as a leading enterprise in China’s microfluidic POCT industry.

Mr. Li Zhenhe, Director and General Manager of Henan High-Tech Venture Capital Co., Ltd., stated:POCT products that combine the advantages of speed, precision, convenience, multi-analyte testing, and room-temperature storage can enhance the diagnostic and therapeutic capabilities of clinical departments in hospitals and primary healthcare institutions. This represents an inevitable development trend driven by both market demand and policy guidance. However, achieving all these advantages simultaneously poses significant technical barriers. The Chengdu Weikang Biology team possesses extensive experience in microfluidic chips, reagents, instruments, raw materials, and clinical applications, enabling their products to embody these benefits while offering a diverse product portfolio that meets the needs of everyone from clinical departments in tertiary Grade A hospitals to primary healthcare facilities. We look forward to Weikang’s rapid market expansion, providing physicians and patients with high-quality microfluidic POCT solutions.

Ms. Yang Lu, Managing Director of Hongzheng Lide Capital, stated:Chengdu Weikang Biology has assembled a team of outstanding talents in the fields of life sciences, microfluidics, and electromechanical automation. The company has conducted profound underlying technological innovations in areas such as antigens and antibodies, nanomaterials, diagnostic reagents, microfluidic chips, and detection instruments, establishing a portfolio of self-developed technical patents. Weikang has pioneered a novel microfluidic POCT technology pathway well-suited for large-scale industrialization in the Chinese market. Building on superior product performance, Weikang has achieved dual breakthroughs by significantly reducing costs while substantially improving yield rates and production capacity. We look forward to seeing Weikang’s microfluidic POCT products expand into more medical scenarios, benefiting a broader population.

Mr. Luo Daoyu, Executive Partner of Shenzhen Xidao Yunying, stated:Chengdu Weikang Biotech is committed to becoming a leading enterprise in China’s microfluidic POCT sector. The core product of its immunodiagnostic platform—a disc-based microfluidic immunoassay POCT device—features compact size, rapid turnaround, high accuracy, and a “sample-in, result-out” workflow, with the capability to simultaneously test for nine analytes. This solution effectively meets the stringent requirements of hospital clinical departments for POCT products. Looking ahead, Weikang is poised to emerge as a distinctive leader in the clinical POCT niche market.

It is understood that Chengdu WeikangSeries B equity financing to be launched soon, accelerate the registration of high-end products, development of new platforms, and market expansion.